Quick Answer
Akebia Therapeutics, Inc. reported Stockholders Equity of $32.61 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +166.3% in Stockholders Equity from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$127.07 million | Q1 2014: $127.87 million | Q2 2014: $121.55 million | Q3 2014: $113.61 million | Q1 2015: $94.61 million | Q2 2015: $149.75 million | Q3 2015: $145.41 million | Q1 2016: $167.76 million | Q2 2016: $133.29 million | Q3 2016: $100.71 million | Q1 2017: $30.62 million | Q2 2017: $57.00 million | Q3 2017: $99.88 million | Q1 2018: $197.10 million | Q2 2018: $165.92 million | Q3 2018: $142.54 million | Q1 2019: $566.38 million | Q2 2019: $519.36 million | Q3 2019: $467.56 million | Q1 2020: $396.36 million | Q2 2020: $370.26 million | Q3 2020: $317.96 million | Q1 2021: $213.89 million | Q2 2021: $174.63 million | Q3 2021: $137.15 million | Q1 2022: $22.58 million | Q2 2022: $58.94 million | Q3 2022: $8.26 million | Q1 2023: -$19.12 million | Q2 2023: -$26.81 million | Q3 2023: -$39.42 million | Q1 2024: -$27.26 million | Q2 2024: -$33.75 million | Q3 2024: -$50.40 million | Q1 2025: $24.58 million | Q2 2025: $29.22 million | Q3 2025: $41.59 million.
- Over the full 15 years of available data (2011 to 2025), Akebia Therapeutics, Inc.'s Stockholders Equity has grown by 167.7%.
- Historical annual values: Fiscal year 2025: $32.61 million | Fiscal year 2024: -$49.19 million | Fiscal year 2023: -$30.58 million | Fiscal year 2022: $5.23 million | Fiscal year 2021: $74.01 million | Fiscal year 2020: $247.62 million | Fiscal year 2019: $394.76 million | Fiscal year 2018: $635.93 million | Fiscal year 2017: $122.57 million | Fiscal year 2016: $68.12 million | Fiscal year 2015: $131.00 million | Fiscal year 2014: $104.08 million | Fiscal year 2013: -$127.07 million | Fiscal year 2012: -$59.59 million | Fiscal year 2011: -$48.19 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: